J-113,397

From Wikipedia, the free encyclopedia
Jump to: navigation, search
J-113,397
J-113,397 structure.png
Systematic (IUPAC) name
1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one
Clinical data
Legal status ?
Identifiers
CAS number 217461-40-0 N
ATC code ?
PubChem CID 5311194
IUPHAR ligand 1691
ChemSpider 4470714 N
ChEMBL CHEMBL357076 N
Synonyms J-113,397
Chemical data
Formula C24H37N3O2 
Mol. mass 399.568 g/mol
 N (what is this?)  (verify)

J-113,397 is an opioid analgesic drug which was the first compound found to be a highly selective antagonist for the nociceptin receptor, also known as the ORL-1 receptor.[1][2] It is several hundred times selective for the ORL-1 receptor over other opioid receptors,[3][4] and its effects in animals include preventing the development of tolerance to morphine,[5] the prevention of hyperalgesia induced by intracerebroventricular administration of nociceptin (orphanin FQ),[6] as well as the stimulation of dopamine release in the striatum,[7] which increases the rewarding effects of cocaine,[8] but may have clinical application in the treatment of Parkinson's disease.[9][10][11]

See also[edit]

References[edit]

  1. ^ Kawamoto H, Ozaki S, Itoh Y, Miyaji M, Arai S, Nakashima H, Kato T, Ohta H, Iwasawa Y. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). Journal of Medicinal Chemistry. 1999 Dec 16;42(25):5061-3. PMID 10602690
  2. ^ De Risi C, Piero Pollini G, Trapella C, Peretto I, Ronzoni S, Giardina GA. A new synthetic approach to 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-benzimidazol-2-one(J-113397), the first non-peptide ORL-1 receptor antagonist. Bioorganic and Medicinal Chemistry. 2001 Jul;9(7):1871-7. PMID 11425589
  3. ^ Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Iwasawa Y, Ohta H. A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist: J-113397. European Journal of Pharmacology. 2000 Jan 17;387(3):R17-8. PMID 10650183
  4. ^ Smith ED, Ariane Vinson N, Zhong D, Berrang BD, Catanzaro JL, Thomas JB, Navarro HA, Gilmour BP, Deschamps J, Carroll FI. A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay. Bioorganic and Medicinal Chemistry. 2008 Jan 15;16(2):822-9. PMID 17976996
  5. ^ Chung S, Pohl S, Zeng J, Civelli O, Reinscheid RK. Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance. Journal of Pharmacology and Experimental Therapeutics. 2006 Jul;318(1):262-7. PMID 16595734
  6. ^ Ozaki S, Kawamoto H, Itoh Y, Miyaji M, Azuma T, Ichikawa D, Nambu H, Iguchi T, Iwasawa Y, Ohta H. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. European Journal of Pharmacology. 2000 Aug 18;402(1-2):45-53. PMID 10940356
  7. ^ Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M, Mercuri NB, Rizzi A, Franchi G, Beani L, Bianchi C, Morari M. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. Journal of Neuroscience. 2004 Jul 28;24(30):6659-66. PMID 15282268
  8. ^ Marquez P, Nguyen AT, Hamid A, Lutfy K. The endogenous OFQ/N/ORL-1 receptor system regulates the rewarding effects of acute cocaine. Neuropharmacology. 2008 Mar;54(3):564-8. PMID 18082848
  9. ^ Marti M, Trapella C, Viaro R, Morari M. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. Journal of Neuroscience. 2007 Feb 7;27(6):1297-307. PMID 17287504
  10. ^ Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiology of Disease. 2008 Jun;30(3):430-8. PMID 18413287
  11. ^ Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH. The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorders. 2008 Oct 15;23(13):1922-5. PMID 18759357